The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | RATIONALE-306: exploring PD-L1 biomarker metrics in advanced ESCC
Eric Raymond, MD, Paris Saint-Joseph Hospital, Paris, France, discusses evaluating PD-L1 expression in advanced esophageal squamous cell carcinoma (ESCC). The combined positive score (CPS) is typically used as the primary metric, however the RATIONALE-306 trial (NCT03783442) utilized the tumor proportion score (TPS) to assess PD-L1 expression not only on tumor cells, but also immune cells, providing a broader analysis compared to CPS. Additionally, TPS offers a slight convenience advantage as it is based on a visual evaluation. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
